Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 12,432 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 12,432 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60. Following the transaction, the insider directly owned 629,943 shares in the company, valued at approximately $3,023,726.40. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total transaction of $61,200.95.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total transaction of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total transaction of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total transaction of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total value of $127,653.45.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total value of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total transaction of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.

Clene Price Performance

Shares of Clene stock opened at $5.19 on Thursday. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The firm has a market cap of $56.31 million, a price-to-earnings ratio of -1.53 and a beta of 0.87. The company has a 50-day moving average of $6.85 and a 200 day moving average of $6.49.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, equities analysts anticipate that Clene Inc. will post -5.19 EPS for the current year.

Institutional Investors Weigh In On Clene

Several large investors have recently bought and sold shares of the business. Scoggin Management LP raised its position in Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after buying an additional 107,250 shares during the last quarter. Lunt Capital Management Inc. boosted its holdings in shares of Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after acquiring an additional 1,250 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Clene in the second quarter worth approximately $47,000. Finally, Jones Financial Companies Lllp purchased a new position in shares of Clene during the third quarter valued at approximately $29,000. 23.28% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. UBS Group reiterated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. D. Boral Capital reissued a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Friday, January 9th. Finally, Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).